Overview

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
An open-label, dose-adjustment extension study to evaluate the safety and efficacy of eltrombopag for treatment of subjects with ITP who have previously been enrolled in the eltrombopag trial TRA108109 (NCT00540423).
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline